Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour
- PMID: 20089110
- DOI: 10.1111/j.1464-410X.2009.09175.x
Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour
Abstract
Objective: To determine whether conformity to standard recommendations of retroperitoneal lymph node dissection (RPLND) after chemotherapy for testicular and primary retroperitoneal nonseminomatous germ cell tumours (NSGCT) and completeness of surgical excision have an effect on oncological outcome.
Patients and methods: This was a retrospective study of patients with testicular and primary retroperitoneal NSGCT, with initial involvement of RPLNs, treated between June 1992 and December 2002 in one institution. We reviewed the clinical, surgical and histological charts of 151 such patients who had a RPLND after first-line platinum-based chemotherapy. The recommendations used to define conformity to RPLND standards were: the indication based on initial and residual lymph node size, shrinkage, extension of dissection and completeness of resection.
Results: RPLND conformed to standard recommendations in 70 of the 151 (46%) patients. Conformity was complete for the surgeon who operated on 48 patients and was 26% of the others. Fifteen patients (10%) relapsed in the retroperitoneum, 14 of whom had initial lymph nodes of > or =5 cm. Two patients (3%) relapsed in the group of 70 patients with conformed and complete RPLND, vs 13 (16%) in the 81 with conformed but incomplete resection or with non-conformed and complete or incomplete RPLND. After a median (range) follow-up of 77 (1.3-186.5) months 132 patients were alive with no evidence of disease, 18 died and one was alive with progressive disease. The limitations of this study were the relatively few patients and that it was retrospective.
Conclusion: There was conformity of RLNPD to the recommendations, and completeness of resection, in half of the patients operated; this might have an effect on oncological outcome. Our data suggest that patients should be treated in tertiary centres.
Similar articles
-
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.BJU Int. 2007 May;99(5):993-7. doi: 10.1111/j.1464-410X.2007.06740.x. BJU Int. 2007. PMID: 17437432
-
[Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].Ai Zheng. 2008 Dec;27(12):1302-6. Ai Zheng. 2008. PMID: 19079998 Chinese.
-
Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?BJU Int. 2008 Aug;102(3):310-4. doi: 10.1111/j.1464-410X.2008.07579.x. Epub 2008 Mar 5. BJU Int. 2008. PMID: 18325053
-
Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.Eur Urol. 2008 Nov;54(5):1004-15. doi: 10.1016/j.eururo.2008.08.022. Epub 2008 Aug 13. Eur Urol. 2008. PMID: 18722704 Review.
-
Surgical management of low-stage nonseminomatous germ cell testicular cancer.BJU Int. 2009 Nov;104(9 Pt B):1362-8. doi: 10.1111/j.1464-410X.2009.08860.x. BJU Int. 2009. PMID: 19840014 Review.
Cited by
-
External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.World J Urol. 2014 Dec;32(6):1573-8. doi: 10.1007/s00345-014-1240-6. Epub 2014 Jan 20. World J Urol. 2014. PMID: 24442607
-
[Diagnostics and treatment of seminomatous germ cell tumors].Urologe A. 2014 Apr;53(4):563-74; quiz 575-6. doi: 10.1007/s00120-013-3378-z. Urologe A. 2014. PMID: 24700191 Review. German.
-
Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.World J Urol. 2021 Jun;39(6):1969-1976. doi: 10.1007/s00345-020-03437-z. Epub 2020 Sep 21. World J Urol. 2021. PMID: 32955662 Free PMC article.
-
[Update on first-line and relapse chemotherapy for testicular cancer].Urologe A. 2013 Nov;52(11):1547-8, 1550-5. doi: 10.1007/s00120-013-3251-0. Urologe A. 2013. PMID: 24126502 German.
-
[Diagnosis, treatment and follow-up of testicular cancer].Urologe A. 2017 Dec;56(12):1623-1636. doi: 10.1007/s00120-017-0543-9. Urologe A. 2017. PMID: 29188346 Review. German.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical